Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9273522 | 0.99 | USP2 (0.53) | USP2ALOX15TSHRMCHR1 | |
| SCHEMBL9100760 | 0.99 | USP2 (0.53) | USP2ALOX15TSHRMCHR1 | |
| SCHEMBL9100764 | 0.99 | USP2 (0.53) | USP2ALOX15TSHRMCHR1 | |
| Hydrochloric Acid SCHEMBL9100578 | 0.97 | USP2 (0.55) | USP2ALOX15NTSR1MCHR1 | |
| Hydrochloric Acid SCHEMBL9100568 | 0.97 | USP2 (0.55) | USP2ALOX15NTSR1MCHR1 | |
| Hydrochloric Acid SCHEMBL9277199 | 0.97 | USP2 (0.55) | USP2ALOX15NTSR1MCHR1 | |
| SCHEMBL9104181 | 0.96 | USP2 (0.50) | USP2ALOX15TSHRMCHR1 | |
| SCHEMBL9104187 | 0.96 | USP2 (0.50) | USP2ALOX15TSHRMCHR1 | |
| Cadaverine Tartrate SCHEMBL9278624 | 0.90 | USP2 (0.46) | USP2ALOX15NTSR1MCHR1 | |
| Cadaverine Tartrate SCHEMBL9100745 | 0.90 | USP2 (0.46) | USP2ALOX15NTSR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | USP2 3248/4885ALOX15 4547/4885TSHR 304/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | USP2 3248/4885ALOX15 4547/4885TSHR 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.